Intellectual Property Law and Access to Medicines (eBook, PDF)
TRIPS Agreement, Health, and Pharmaceuticals
Redaktion: Ragavan, Srividhya; Vanni, Amaka
39,95 €
39,95 €
inkl. MwSt.
Sofort per Download lieferbar
20 °P sammeln
39,95 €
Als Download kaufen
39,95 €
inkl. MwSt.
Sofort per Download lieferbar
20 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
39,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
20 °P sammeln
Intellectual Property Law and Access to Medicines (eBook, PDF)
TRIPS Agreement, Health, and Pharmaceuticals
Redaktion: Ragavan, Srividhya; Vanni, Amaka
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book details the historical trajectory of the global struggle to access medicines.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 8.38MB
This book details the historical trajectory of the global struggle to access medicines.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 522
- Erscheinungstermin: 28. Juli 2021
- Englisch
- ISBN-13: 9781000398700
- Artikelnr.: 62241444
- Verlag: Taylor & Francis
- Seitenzahl: 522
- Erscheinungstermin: 28. Juli 2021
- Englisch
- ISBN-13: 9781000398700
- Artikelnr.: 62241444
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Srividhya Ragavan is a Professor of Law and Director of the India Program at Texas A&M University School of Law, Texas, United States. Amaka Vanni is an Assistant Professor at School of Law, University of Leeds, United Kingdom.
Introduction Access to Medicine and TRIPS Agreement: A Historiographic
Mapping of the Tradescape Srividhya Ragavan and Amaka Vanni Part I:
International Norm Setting and Patent Metamorphosis: First Generation 1.
World Trade Organization: A Barrier to Global Public Health? Srividhya
Ragavan 2. World Health Organization: Contributions to Access to Health and
TRIPS Agreement Discourse Susan Isiko trba 3. From TRIPS to Access to
Medicines: What's There in Between? Sergio Napolitano 4. Free Trade
Agreements: Longer, Further, Deeper Impact on Pharmaceutical Patents Bryan
Mercurio 5. From the TPP to USMCA: A High-Powered Battle over Biologics
Burcu Kilic 6. African Union Continental Free Trade Area: Opportunities for
New Regional Discourse? J. Janewa Osei-Tutu 7. U.S. Litigated Government
Funded Patents in Europe and Japan: A First Look Teo Firpo and Michael S.
Mireles Part II: State Action and the Access to Medicine Debate: Second
Generation 8. Brazil: Patent Barriers and Access to Medicine through Public
Health System Gabriela Costa Chaves, Maria Auxiladora Oliveira, and Jorge
Antonio Zepeda Bermudez 9. China: From Struggle to Surge: China's TRIPS
Experience and its Lessons for Access to Medicines Peter K. Yu 10. Canada:
Access to Medicine in High-Income Countries Gaëlle Groux and Jeremy de Beer
11. India: Pharmaceutical Patents and Evergreen Battle for Access to
Medicine Anand Grover 12. South Africa's Three Decades of Access to
Medicine Discourse: Blight or Benefit Caroline B. Ncube 13. Thailand:
Shooting Star for Access to Medicine through Compulsory Licensing Van Anh
Le 14. United States: Unilateral Norm Setting Using Special 301 Michael
Palmedo Part III: Global Patterns and Emerging Issues: Third Generation
15. Access to Medicines Activism: Collaboration, Conflicts, and
Complementarities Brook K. Baker 16. GTPI: Experiences to Overcome IP
Barriers to Increase Access to Medicine Felipe de Carvalho Borges da
Fonseca, Marcela Fogaça Vieira, and Pedro Villardi 17. Private Sector:
Right to Health Responsibilities of Pharmaceutical Companies Emmanuel
Kolawole Oke 18. Competition: Can Excessive Pricing be Fixed through Abuse
of Dominant Position? Shirin Syed 19. The Unique World of Pharmaceutical
Intellectual Property Rights Emily Michiko Morris 20. Innovation Policies:
Roadblocks to Establishing Sustainable Pharmaceutical Innovation Policies
Doris Estelle Long 21. Not Just Patents and Data Exclusivity: The Role of
Trademarks in Integrated IP Strategy - Where Lies the Public Interest?
Graham Dutfield 22. Indigenous Knowledge: Bridging with Modern Medicine
Anthony C. K. Kakooza 23. Digital Divide and Access to Medicine: The Debate
Swaraj Paul Barooah Part IV: COVID-19 and Access to Medicines Lessons from
COVID-19 for Medicine Access Amaka Vanni
Mapping of the Tradescape Srividhya Ragavan and Amaka Vanni Part I:
International Norm Setting and Patent Metamorphosis: First Generation 1.
World Trade Organization: A Barrier to Global Public Health? Srividhya
Ragavan 2. World Health Organization: Contributions to Access to Health and
TRIPS Agreement Discourse Susan Isiko trba 3. From TRIPS to Access to
Medicines: What's There in Between? Sergio Napolitano 4. Free Trade
Agreements: Longer, Further, Deeper Impact on Pharmaceutical Patents Bryan
Mercurio 5. From the TPP to USMCA: A High-Powered Battle over Biologics
Burcu Kilic 6. African Union Continental Free Trade Area: Opportunities for
New Regional Discourse? J. Janewa Osei-Tutu 7. U.S. Litigated Government
Funded Patents in Europe and Japan: A First Look Teo Firpo and Michael S.
Mireles Part II: State Action and the Access to Medicine Debate: Second
Generation 8. Brazil: Patent Barriers and Access to Medicine through Public
Health System Gabriela Costa Chaves, Maria Auxiladora Oliveira, and Jorge
Antonio Zepeda Bermudez 9. China: From Struggle to Surge: China's TRIPS
Experience and its Lessons for Access to Medicines Peter K. Yu 10. Canada:
Access to Medicine in High-Income Countries Gaëlle Groux and Jeremy de Beer
11. India: Pharmaceutical Patents and Evergreen Battle for Access to
Medicine Anand Grover 12. South Africa's Three Decades of Access to
Medicine Discourse: Blight or Benefit Caroline B. Ncube 13. Thailand:
Shooting Star for Access to Medicine through Compulsory Licensing Van Anh
Le 14. United States: Unilateral Norm Setting Using Special 301 Michael
Palmedo Part III: Global Patterns and Emerging Issues: Third Generation
15. Access to Medicines Activism: Collaboration, Conflicts, and
Complementarities Brook K. Baker 16. GTPI: Experiences to Overcome IP
Barriers to Increase Access to Medicine Felipe de Carvalho Borges da
Fonseca, Marcela Fogaça Vieira, and Pedro Villardi 17. Private Sector:
Right to Health Responsibilities of Pharmaceutical Companies Emmanuel
Kolawole Oke 18. Competition: Can Excessive Pricing be Fixed through Abuse
of Dominant Position? Shirin Syed 19. The Unique World of Pharmaceutical
Intellectual Property Rights Emily Michiko Morris 20. Innovation Policies:
Roadblocks to Establishing Sustainable Pharmaceutical Innovation Policies
Doris Estelle Long 21. Not Just Patents and Data Exclusivity: The Role of
Trademarks in Integrated IP Strategy - Where Lies the Public Interest?
Graham Dutfield 22. Indigenous Knowledge: Bridging with Modern Medicine
Anthony C. K. Kakooza 23. Digital Divide and Access to Medicine: The Debate
Swaraj Paul Barooah Part IV: COVID-19 and Access to Medicines Lessons from
COVID-19 for Medicine Access Amaka Vanni
Introduction Access to Medicine and TRIPS Agreement: A Historiographic
Mapping of the Tradescape Srividhya Ragavan and Amaka Vanni Part I:
International Norm Setting and Patent Metamorphosis: First Generation 1.
World Trade Organization: A Barrier to Global Public Health? Srividhya
Ragavan 2. World Health Organization: Contributions to Access to Health and
TRIPS Agreement Discourse Susan Isiko trba 3. From TRIPS to Access to
Medicines: What's There in Between? Sergio Napolitano 4. Free Trade
Agreements: Longer, Further, Deeper Impact on Pharmaceutical Patents Bryan
Mercurio 5. From the TPP to USMCA: A High-Powered Battle over Biologics
Burcu Kilic 6. African Union Continental Free Trade Area: Opportunities for
New Regional Discourse? J. Janewa Osei-Tutu 7. U.S. Litigated Government
Funded Patents in Europe and Japan: A First Look Teo Firpo and Michael S.
Mireles Part II: State Action and the Access to Medicine Debate: Second
Generation 8. Brazil: Patent Barriers and Access to Medicine through Public
Health System Gabriela Costa Chaves, Maria Auxiladora Oliveira, and Jorge
Antonio Zepeda Bermudez 9. China: From Struggle to Surge: China's TRIPS
Experience and its Lessons for Access to Medicines Peter K. Yu 10. Canada:
Access to Medicine in High-Income Countries Gaëlle Groux and Jeremy de Beer
11. India: Pharmaceutical Patents and Evergreen Battle for Access to
Medicine Anand Grover 12. South Africa's Three Decades of Access to
Medicine Discourse: Blight or Benefit Caroline B. Ncube 13. Thailand:
Shooting Star for Access to Medicine through Compulsory Licensing Van Anh
Le 14. United States: Unilateral Norm Setting Using Special 301 Michael
Palmedo Part III: Global Patterns and Emerging Issues: Third Generation
15. Access to Medicines Activism: Collaboration, Conflicts, and
Complementarities Brook K. Baker 16. GTPI: Experiences to Overcome IP
Barriers to Increase Access to Medicine Felipe de Carvalho Borges da
Fonseca, Marcela Fogaça Vieira, and Pedro Villardi 17. Private Sector:
Right to Health Responsibilities of Pharmaceutical Companies Emmanuel
Kolawole Oke 18. Competition: Can Excessive Pricing be Fixed through Abuse
of Dominant Position? Shirin Syed 19. The Unique World of Pharmaceutical
Intellectual Property Rights Emily Michiko Morris 20. Innovation Policies:
Roadblocks to Establishing Sustainable Pharmaceutical Innovation Policies
Doris Estelle Long 21. Not Just Patents and Data Exclusivity: The Role of
Trademarks in Integrated IP Strategy - Where Lies the Public Interest?
Graham Dutfield 22. Indigenous Knowledge: Bridging with Modern Medicine
Anthony C. K. Kakooza 23. Digital Divide and Access to Medicine: The Debate
Swaraj Paul Barooah Part IV: COVID-19 and Access to Medicines Lessons from
COVID-19 for Medicine Access Amaka Vanni
Mapping of the Tradescape Srividhya Ragavan and Amaka Vanni Part I:
International Norm Setting and Patent Metamorphosis: First Generation 1.
World Trade Organization: A Barrier to Global Public Health? Srividhya
Ragavan 2. World Health Organization: Contributions to Access to Health and
TRIPS Agreement Discourse Susan Isiko trba 3. From TRIPS to Access to
Medicines: What's There in Between? Sergio Napolitano 4. Free Trade
Agreements: Longer, Further, Deeper Impact on Pharmaceutical Patents Bryan
Mercurio 5. From the TPP to USMCA: A High-Powered Battle over Biologics
Burcu Kilic 6. African Union Continental Free Trade Area: Opportunities for
New Regional Discourse? J. Janewa Osei-Tutu 7. U.S. Litigated Government
Funded Patents in Europe and Japan: A First Look Teo Firpo and Michael S.
Mireles Part II: State Action and the Access to Medicine Debate: Second
Generation 8. Brazil: Patent Barriers and Access to Medicine through Public
Health System Gabriela Costa Chaves, Maria Auxiladora Oliveira, and Jorge
Antonio Zepeda Bermudez 9. China: From Struggle to Surge: China's TRIPS
Experience and its Lessons for Access to Medicines Peter K. Yu 10. Canada:
Access to Medicine in High-Income Countries Gaëlle Groux and Jeremy de Beer
11. India: Pharmaceutical Patents and Evergreen Battle for Access to
Medicine Anand Grover 12. South Africa's Three Decades of Access to
Medicine Discourse: Blight or Benefit Caroline B. Ncube 13. Thailand:
Shooting Star for Access to Medicine through Compulsory Licensing Van Anh
Le 14. United States: Unilateral Norm Setting Using Special 301 Michael
Palmedo Part III: Global Patterns and Emerging Issues: Third Generation
15. Access to Medicines Activism: Collaboration, Conflicts, and
Complementarities Brook K. Baker 16. GTPI: Experiences to Overcome IP
Barriers to Increase Access to Medicine Felipe de Carvalho Borges da
Fonseca, Marcela Fogaça Vieira, and Pedro Villardi 17. Private Sector:
Right to Health Responsibilities of Pharmaceutical Companies Emmanuel
Kolawole Oke 18. Competition: Can Excessive Pricing be Fixed through Abuse
of Dominant Position? Shirin Syed 19. The Unique World of Pharmaceutical
Intellectual Property Rights Emily Michiko Morris 20. Innovation Policies:
Roadblocks to Establishing Sustainable Pharmaceutical Innovation Policies
Doris Estelle Long 21. Not Just Patents and Data Exclusivity: The Role of
Trademarks in Integrated IP Strategy - Where Lies the Public Interest?
Graham Dutfield 22. Indigenous Knowledge: Bridging with Modern Medicine
Anthony C. K. Kakooza 23. Digital Divide and Access to Medicine: The Debate
Swaraj Paul Barooah Part IV: COVID-19 and Access to Medicines Lessons from
COVID-19 for Medicine Access Amaka Vanni